Insider Selling: David M. Stack Sells 15,000 Shares of Pacira Pharmaceuticals Stock (PCRX)
Pacira Pharmaceuticals (NASDAQ:PCRX) CEO David M. Stack sold 15,000 shares of Pacira Pharmaceuticals stock on the open market in a transaction that occurred on Tuesday, July 15th. The shares were sold at an average price of $86.75, for a total transaction of $1,301,250.00. Following the transaction, the chief executive officer now directly owns 1,208 shares in the company, valued at approximately $104,794. The sale was disclosed in a document filed with the SEC, which is available at this link.
Pacira Pharmaceuticals (NASDAQ:PCRX) traded down 1.29% during mid-day trading on Wednesday, hitting $85.14. The stock had a trading volume of 320,383 shares. Pacira Pharmaceuticals has a one year low of $30.75 and a one year high of $94.30. The stock has a 50-day moving average of $85.54 and a 200-day moving average of $73.20. The company’s market cap is $3.036 billion.
Pacira Pharmaceuticals (NASDAQ:PCRX) last announced its earnings results on Thursday, May 1st. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.13. The company had revenue of $36.70 million for the quarter, compared to the consensus estimate of $35.40 million. The company’s revenue for the quarter was up 216.4% on a year-over-year basis. On average, analysts predict that Pacira Pharmaceuticals will post $-0.53 earnings per share for the current fiscal year.
Several analysts have recently commented on the stock. Analysts at Barclays raised their price target on shares of Pacira Pharmaceuticals from $85.00 to $107.00 in a research note on Wednesday. They now have an “overweight” rating on the stock. Separately, analysts at Canaccord Genuity initiated coverage on shares of Pacira Pharmaceuticals in a research note on Friday, June 27th. They set a “buy” rating and a $109.00 price target on the stock. They noted that the move was a valuation call. Finally, analysts at JMP Securities initiated coverage on shares of Pacira Pharmaceuticals in a research note on Tuesday, June 17th. They set a “market perform” rating on the stock. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $87.68.
Pacira Pharmaceuticals, Inc is a United States-based pharmaceutical company. The Company develops non-opioid products for postsurgical pain control.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.